Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Opin Oncol. 2008 May;20(3):270-4. doi: 10.1097/CCO.0b013e3282f4cf5f.

Salivary gland carcinomas: molecular abnormalities as potential therapeutic targets.

Author information

1
Department of General Medical Oncology, University Hospital Gasthuisberg, Catholic University Leuven, Herestraat, Leuven, Belgium. hans.prenen@uz.kuleuven.be

Abstract

PURPOSE OF REVIEW:

Salivary gland neoplasms are composed of histopathologically and clinically diverse entities. The reported response rates of salivary gland tumors to chemotherapy are generally poor. Molecular studies have provided some information on their biology and have identified new targets with therapeutic potential.

RECENT FINDINGS:

Several agents are currently being tested that target molecular signaling and cancer cell biology. The pathways involved include but are not limited to vascular endothelial growth factor and epidermal growth factor receptors. Novel treatments under evaluation include tyrosine kinase inhibitors, antibodies, angiogenesis inhibitors, demethylating agents, and proteasome inhibitors.

SUMMARY:

Some of these new targeted approaches hold promise for our future ability to treat patients with salivary gland cancer unresponsive to traditional therapy, but others were disappointing. The presence of the molecular target alone is not sufficient to guarantee an antitumor effect with targeted therapy. The success of these molecular-targeted agents depends on the molecular abnormalities involved in carcinogenesis.

PMID:
18391625
DOI:
10.1097/CCO.0b013e3282f4cf5f
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wolters Kluwer
    Loading ...
    Support Center